Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Biotech

Large Cap

News

Health Care

Movers

General

Novo Nordisk revela datos sobre Amycretina, un nuevo medicamento para pérdida de peso, que mostró una baja del 13,1% en peso en 12 semanas.

Novo Nordisk presenta resultados de su nuevo fármaco para pérdida de peso, Amycretina

Novo Nordisk AS

Novo Resources Corp Warrants (27/08/2023)

Novo Integrated Sciences, Inc. - Common Stock

Novo Integrated Sciences Inc

In a surprising twist, two of the most unlikely allies – billionaire Elon Musk and Sen. Bernie Sanders – are standing together on one issue: the high cost of health care in America. Both agree that Americans are being charged way too much for <a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear">essential medications like Ozempic</a> and Wegovy, which treat diabetes and obesity.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Bernie Sanders, a longtime advocate for affordable health care, has been vocal about Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the Danish company behind these drugs, charging American patients almost 10 times more than they charge in other countries like Germany.
<a href="https://www.benzinga.com/general/biotech/24/09/41010577/novo-nordisk-to-consider-ways-for-patients-to-affordably-access-weight-loss-drugs-ozempic-wegovy-">A month's prescription for Wegovy</a> costs $1,349 in the U.S., compared to $186 in Denmark, $140 in Germany, and $92 in the U.K.
Trending: Teens may never need wisdom teeth removed thanks to this MedTech Company –<a href="https://www.benzinga.com/money/triagenics"> Be an early investor for just $300 for 100 shares!</a>
During a recent subcommittee hearing, Sanders called out Novo Nordisk&#8217;s CEO and demanded that Americans be treated fairly. "All we are saying, Mr. Jørgensen, is treat the American people the same way that you treat people all over the world – stop ripping us off."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f6a8;&#x1f1fa;&#x1f1f8;SEN. BERNIE SANDERS: ELON IS RIGHT ABOUT SOLVING OBESITY &quot;Elon Musk, not one of my usual allies, recently tweeted that solving obesity reduces the risk of diseases like diabetes and improves quality of life. He's right—we need to make appetite inhibitors available to… <a href="https://t.co/vmPzNNc15B">pic.twitter.com/vmPzNNc15B</a>
&mdash; Mario Nawfal (@MarioNawfal) <a href="https://twitter.com/MarioNawfal/status/1838737435653460028?ref_src=twsrc%5Etfw">September 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Elon Musk, known for his clashes with Sanders over income inequality, surprised many by siding with the senator. He shared his struggles with weight and revealed he had used Wegovy to help him slim down.&nbsp;
Trending: Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500.</a>
"Solving obesity greatly reduces the risk of other diseases, especially diabetes, and improves quality of life," Sanders quoted Musk as saying. And Musk followed up with, "I really am with Bernie on this one."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I really am with Bernie on this one
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1838758206585094625?ref_src=twsrc%5Etfw">September 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Novo Nordisk's CEO, Lars Fruergaard Jørgensen, admitted that a huge chunk of the company's revenue from these drugs comes from the U.S., but he tried to shift the blame to PBMs, who he says pocket 74 cents of every dollar made. This system, he argued, keeps prices high because PBMs get paid more when the list price is higher.
Trending: General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"> investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50/share with a $1,000 minimum.</a>
Sanders wasn't buying it. He revealed that he had gotten a written promise from three major PBMs that they wouldn't drop coverage for Novo Nordisk's drugs if the company lowered its prices. But Jørgensen acted surprised and claimed he hadn't heard of any such deal.
The Federal Trade Commission (FTC) also released a <a href="https://www.ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdf">report</a> highlighting how pharmacy benefit managers (PBMs) are profiting at the expense of patients. These middlemen, who manage prescription drug benefits for insurers and employers, have been inflating drug prices and squeezing independent pharmacies.&nbsp;
According to a report, six major corporations manage about 90% of all prescriptions in the United States. This gives them the authority to set exorbitant medicine costs. Because of the high expense of prescription drugs, almost 30% of Americans have reported skipping dosages or limiting them.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
FTC Chair Lina M. Khan stated that the report &#8220;Details how PBMs can squeeze independent pharmacies that many Americans – especially those in rural communities – depend on for essential care. The FTC will continue using all our tools and authorities to scrutinize dominant players across health care markets and ensure Americans can access affordable health care.&#8221;
See Also: Are you richer than most people you know?<a href="https://www.benzinga.com/money/are-you-richer-than-most-people"> Here&#8217;s the net worth you need at every age to be above average.</a>
Mark Cuban, another billionaire entrepreneur and owner of Cost Plus Drugs, quickly responded to the FTC's findings. In a tweet, <a href="https://www.benzinga.com/personal-finance/24/07/39799717/patients-pay-the-price-as-drug-middlemen-profit-says-ftc-report-mark-cubans-take-anyone-surprise">he pointed out the obvious</a>: "Anyone surprised by this? Please share with every CEO, CFO, and HR person you know. If you are a shareholder or Wall Street analyst, ask your portfolio companies who their PBM is, not if they are being ripped off, but how badly."
In a country where health care costs are sky-high and outcomes lag behind many other developed nations, it's rare to see such agreement across the political spectrum. But when both a billionaire tech mogul and a democratic socialist senator are on the same side, it might be time to take notice.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
</ul>

Personal Finance

'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas">many investors&#8217; favorite stocks</a> over the last week — here&#8217;s a look at some of our top stories.
The Dow Jones Industrial Average hit a record high Friday as investors analyzed data showing continued progress in lowering inflation. Wall Street posted its third straight week of gains.
The S&amp;P 500 and Dow both rose about 0.6% for the week, while the Nasdaq climbed nearly 1%. The personal consumption expenditures index, the Federal Reserve&#8217;s preferred inflation measure, increased 2.2% in August compared to the previous year, coming in below economists&#8217; expectations. 
This followed the Federal Reserve&#8217;s 0.5% interest rate cut on Sept. 18, the first in <a href="https://www.benzinga.com/markets/equities/24/09/41074448/latest-inflation-data-cements-feds-interest-rate-call-s-p-500-hits-all-time-high-biden-adviser-b">more than four years</a>.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week&#8217;s most bullish and bearish posts that are worth another look.
<h3 class="wp-block-heading">The Bulls</h3>
&#8220;<a href="https://www.benzinga.com/news/24/09/41005053/apple-iphone-to-fuel-96-of-2025-revenue-analyst-says-a-safer-bet-than-ai-heavy-amazon-alphabet-micro">Apple iPhone To Fuel 96% Of 2025 Revenue, Analyst Predicts: A Safer Bet Than AI-Heavy Amazon, Alphabet, Microsoft, Meta?</a>&#8221; by <a href="https://www.benzinga.com/author/anusuya-lahiri-0">Anusuya Lahiri</a>, highlights an analyst&#8217;s projection that Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) will derive 96% of its 2025 revenue from iPhone sales, positioning it as a safer investment than AI-focused giants like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
&#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41059326/shiba-inu-soars-29-on-shi-stablecoin-update-lead-developer-shytoshi-kusama-teases-breakout">Shiba Inu Soars 29% On SHI Stablecoin Update: Lead Developer Shytoshi Kusama Teases Breakout</a>,&#8221; by <a href="https://www.benzinga.com/author/aniket-verma">Aniket Verma</a>, reports that Shytoshi Kusama teased the impending launch of the SHI stablecoin, which is seen as a crucial development for Shibarium, sparking excitement across the Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) ecosystem.
&#8220;<a href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic">Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users</a>,&#8221; by <a href="https://www.benzinga.com/author/vandana-singh">Vandana Singh</a>, reports that a new study found Novo Nordisk A/S&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide, sold as Ozempic and Wegovy, may lower the risk of opioid overdose in patients with both type 2 diabetes and opioid use disorder.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/general/education/24/09/41031059/after-fed-rate-cuts-is-tesla-nvidia-apple-or-amazon-the-best-investment-poll-reveals-top-magnif">After Fed Rate Cuts, Is Tesla, Nvidia, Apple, Or Amazon The Best Investment? Poll Reveals Top Magnificent 7 Stock</a>
<a href="https://www.benzinga.com/news/24/09/41034882/billionaire-tech-ceo-makes-cameo-in-zuckerbergs-meta-connect-show">Billionaire Tech CEO Makes Cameo In Zuckerberg&#8217;s Meta Connect Show</a>
<a href="https://www.benzinga.com/markets/equities/24/09/41023892/palantir-and-apa-amp-up-ai-alliance-multi-million-dollar-deal-to-transform-oil-gas-operations">Palantir And APA Amp Up AI Alliance: Multi-Million Dollar Deal To Transform Oil &amp; Gas Operations</a>
The Bears
&#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40995280/tesla-bull-dampens-enthusiasm-regarding-1010-robotaxi-event-but-heres-what-would-ta">Tesla Bull Dampens Enthusiasm Regarding 10/10 Robotaxi Event But Here&#8217;s What Would Take To Strengthen Fledgling Stock Recovery</a>,&#8221; by <a href="https://www.benzinga.com/author/shanthi-rexaline">Shanthi Rexaline</a>, covers Gary Black&#8216;s skepticism about Tesla Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) upcoming Robotaxi event as a stock catalyst, while highlighting optimism for a potential sub-$30K compact EV launch that could drive long-term growth for Tesla.
&#8220;<a href="https://www.benzinga.com/news/24/09/41016947/crowdstrike-executive-struck-by-regret-in-house-hearing-says-company-determined-to-prevent-instances">CrowdStrike Executive Struck By Regret In House Hearing, Says Company Determined To Prevent Instances Like Microsoft Outage From Repeating</a>,&#8221; by <a href="https://www.benzinga.com/author/ananya-gairola">Ananya Gairola</a>, reports Adam Meyers of CrowdStrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) apologized to lawmakers for the July global outage caused by a faulty update affecting systems running Microsoft software, promising to prevent future occurrences.
&#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41059769/peter-schiff-wants-to-know-if-bitcoin-fans-really-care-about-king-crypto-underperforming-g">Peter Schiff Wants To Know If Bitcoin Fans Really Care About King Crypto Underperforming Gold</a>,&#8221; by <a href="https://www.benzinga.com/author/aniket-verma">Aniket Verma</a>, highlights Peter Schiff&#8216;s critique of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investors for ignoring its 35% decline against gold since November 2021, despite significant media hype and interest in the cryptocurrency.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41000698/a-deflationary-nuclear-bomb-is-ticking-warns-economist-even-as-inflation-risks-wane">A &#8216;Deflationary Nuclear Bomb&#8217; Is Ticking, Warns Economist, Even As Inflation Risks Wane: &#8216;Cheaper It Gets, Cheaper Everything Gets&#8217;</a>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41049089/treasury-bond-etf-under-pressure-ahead-of-key-inflation-data-what-investors-should-know">Treasury Bond ETF Under Pressure Ahead Of Key Inflation Data: What Investors Should Know</a>
<a href="https://www.benzinga.com/markets/equities/24/09/41053761/american-eagle-sues-amazon-for-trademark-infringement-report">American Eagle Sues Amazon for Trademark Infringement: Report</a>
Keep up with all the latest breaking news and trading ideas by following<a href="https://twitter.com/Benzinga"> Benzinga</a><a href="http://twitter.com/Benzinga"> on Twitter</a>.
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Long Ideas

Short Ideas

Tech

Trading Ideas

$BTC

$SHIB

AAPL

AMZN

CRWD

GOOG

GOOGL

MSFT

TSLA

Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease

The Federal Reserve's preferred measure of inflation, the personal consumption expenditures index, grew less than economists expected in August at 2.2% <a href="https://www.benzinga.com/news/econ-s/24/09/41066122/feds-preferred-inflation-gauge-comes-in-below-expectations-for-august-easing-concerns-about-rising-p">year-over-year</a>. The data comes on the heels of the Federal Reserve's 0.5% interest rate cut issued Sept. 18, the first in <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">more than four years</a>.&nbsp;
The inflation data supports another 0.5% interest rate cut in November, RSM US LLP Chief Economist Joseph Brusuelas said in a Friday tweet. "This is what an economic expansion looks like at full employment," <a href="https://www.benzinga.com/news/24/09/41068393/inflation-decline-strengthens-confidence-in-feds-interest-rate-cut-if-you-were-second-guessing-the-f">he said</a>.&nbsp;
The S&amp;P 500 traded at all-time highs above the 5,700 level <a href="https://www.benzinga.com/markets/equities/24/09/41029448/s-p-500-hits-all-time-highs-nasdaq-100-tops-20k-ahead-of-key-economic-data-whats-driving-markets">this week</a>.
<h1 class="wp-block-heading">Brainard Touts China EV Ban In Detroit</h1>
Lael Brainard, the director of the National Economic Council and a former Federal Reserve board member, spoke in favor of the Biden administration's proposed ban on Chinese electric vehicles Monday at the Detroit Economic Club, the same day <a href="https://www.benzinga.com/markets/asia/24/09/40981254/chinese-vehicle-tech-faces-biden-administration-ban-over-national-security-concerns-china-ev-stocks">details of the proposal</a> were released. The U.S. Commerce Department aims to block the import and sale of Chinese-made vehicles with key communications and automated driving systems on the basis of national security concerns. Additionally, a 100% tariff on Chinese electric vehicles imposed by the Biden administration took effect Friday. 
"We will not allow cars driving on U.S. roads if they are using Chinese software and hardware systems," Brainard <a href="https://www.benzinga.com/markets/asia/24/09/40987608/biggest-risk-for-us-autos-biden-advisor-outlines-steps-to-counter-chinese-influence-on-the-industry">told the DEC</a>. "We think this is very important from a national security point of view."
<h1 class="wp-block-heading">Meta Platforms Dives Deeper Into AI, Virtual Reality</h1>
Facebook parent company Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) announced its latest Quest 3S virtual reality headset at the Meta Connect 2024 conference Wednesday along with updates to its Llama artificial intelligence platform and Ray-Ban smart glasses. CEO Mark Zuckerberg introduced a prototype for Orion, Meta's holographic <a href="https://www.benzinga.com/news/24/09/41032461/meta-unveils-new-ai-features-quest-3s-llama-3-2-holographic-orion-glasses-at-connect-2024-we-are-get">augmented reality glasses</a>. 
"This isn't passthrough. This is the physical world with holograms laid on it," Zuckerberg said.
<h1 class="wp-block-heading">China's Stimulus Triggers Stock Rally</h1>
The People's Bank of China announced <a href="https://www.benzinga.com/markets/asia/24/09/41003814/chinese-stocks-jump-as-central-bank-unveils-major-stimulus-to-spur-economy-a-step-in-the-right-direc">stimulus measures this week</a> that will inject approximately $140 billion (1 trillion yuan) in liquidity into the country's banking system as well as a reduction in the mortgage rate, sending U.S.-traded China stocks and ETFs such as e-commerce giant Alibaba Group Holding Ltd &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and electric vehicle manufacturer Nio Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) higher. 
Billionaire hedge fund manager David Tepper told CNBC's "Squawk Box" that he's building <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41050711/stocks-rise-as-china-signals-more-stimulus-billionaire-david-tepper-bets-big-on-everythi">positions in Chinese stocks</a>. "I didn't know that they were going to bring out the big guns," Tepper of the country's stimulus plans.&nbsp;
<h1 class="wp-block-heading">Bernie Sanders Blasts Ozempic Cost</h1>
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) CEO Lars Jorgensen faced questions from the Senate Health, Education, Labor and Pensions Committee Tuesday about the high prices of the drugs Ozempic and Wegovy. 
Wegovy, the weight loss version of diabetes drug Ozempic, costs $1,349 monthly in the U.S. versus $186 in Denmark, $140 in Germany and $92 in the U.K., according to the committee.
"You're making huge amounts of money in this country and you're charging us far more and you haven't given me an answer as to why," Sen. Bernie Sanders, the committee's chair, said to Jorgensen during the hearing.
The CEO said: "Anything that will help patients get access to affordable medicine, we'll be happy to look into."
Photo: Shutterstock.

Global

Economics

Markets

BABA

Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 5 years by 22.36% on an annualized basis producing an average annual return of 36.66%. Currently, Novo Nordisk has a market capitalization of $536.41 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 5 years ago, it would be worth $4,660.74 today based on a price of $120.51 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727456441_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Shares of Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) fell sharply in today's pre-market trading after the SEC charged the company, two former executives for misleading claims about <a href="https://www.benzinga.com/quote/SAVA/news">Alzheimer&#8217;s clinical trial</a>.
Cassava Sciences shares dipped 10.8% to $28.40 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) shares tumbled 16.4% to $3.7600 in pre-market trading after the company announced a proposed public offering.</li>
<li>Uranium Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UEC#NYSE">UEC</a>) shares declined 5% to $6.05 in pre-market trading.</li>
<li>Udemy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) shares fell 4.6% to $7.76 in pre-market trading.</li>
<li>TORM plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) shares declined 4% to $33.96 in pre-market trading.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) shares declined 3.2% to $35.70 in pre-market trading after gaining over 2% on Thursday.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares fell 2.6% to $121.05 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41061540/s-p-hits-new-record-high-following-economic-reports-investor-optimism-improves-further-fear-index-r">S&amp;P Hits New Record High Following Economic Reports: Investor Optimism Improves Further, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

NVNO

SAVA

TRMD

UDMY

Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session

On Thursday, Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) entered a technology development partnership with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/ac41039378/evotec-and-novo-nordisk-enter-into-technology-development-partnership-to-support-next-generation-" rel="noreferrer noopener">in cell therapy</a>.
Evotec and Novo Nordisk have significant expertise and a strategic focus on supporting stem cell-based therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39419032/german-drug-developer-evotec-seeks-adviser-input-as-takeover-concerns-mount" rel="noreferrer noopener">German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount</a>.
To provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialization, the companies will collaborate on developing advanced technologies in support thereof.
Under the collaboration agreement, Novo Nordisk will fund technology development activities at Evotec's R&amp;D site in Göttingen, Germany and at Evotec's certified cell therapy manufacturing facility in Modena, Italy.
Novo Nordisk has the option to obtain exclusive rights to utilize the results of the collaboration for a pre-defined therapeutic area.
Evotec receives R&amp;D funding, an undisclosed upfront, and possible milestone and royalty payments.
Cord Dohrmann, Chief Scientific Officer of Evotec, said: "Cell therapies have already proven to be highly effective and have the potential to become functional cures in many disease areas. Stem cell-based cell therapy is a promising approach to modulate and scale cell therapies to ultimately provide tailor-made, off-the-shelf cell therapies at reasonable costs."
Citing Sydbank analysts, Reuters noted that Novo Nordisk's stem cell-based therapies for diabetes and cardiovascular diseases are still in the exploratory phase, and the collaboration with Evotec aims to unlock this potential further.
Reuters also highlighted Warburg Research analyst who suggested the partnership could be tied to Evotec's beta-cell implant program QR-Beta, with the initial upfront payment likely covering capacity, manpower, and a cost margin.
Price Action: EVO stock is up 4.80% at $3.49 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41046485/whats-going-on-with-nvidia-braodcom-intel-and-other-chip-stocks-on-thursday" target="_blank" rel="noreferrer noopener">What's Going On With Nvidia, Broadcom, Intel, And Other Chip Stocks On Thursday?</a></li>
</ul>
Image via Evotec

Contracts

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

On Thursday, Vivani Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) announced that the Bellberry Human Research Ethics Committee has approved, and the Therapeutic Goods Administration in Australia has formally acknowledged a first-in-human clinical trial of the company's miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects.
What Happened: "Securing regulatory approval keeps us on schedule to initiate this trial in Australia in the fourth quarter of 2024," said Vivani President and CEO Adam Mendelsohn.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39726263/exclusive-vivani-medical-outlines-plans-to-kickstart-first-clinical-study-for-miniature-glp-1-obe" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year</a>.
LIBERATE-1 will be a randomized investigation of the safety, tolerability, and pharmacokinetic profile of the exenatide NanoPortal implant in obese or overweight subjects.
The trial will enroll participants who will be titrated on weekly semaglutide injections for 8 weeks (0.25 mg/week for 4 weeks followed by 0.5 mg/week for 4 weeks) before being randomized to receive a single administration of Vivani's exenatide implant (n=8), weekly exenatide injections (n=8), or weekly 1 mg semaglutide injections (n=8) for 9-week treatment duration.
Weight changes will be measured. The trial is expected to be initiated later this year, and data is projected to be available in 2025.
Why It Matters: "Preclinical <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40704367/exclusive-vivani-medical-reveals-positive-preclinical-liver-fat-results-from-miniature-glp-1-impl" rel="noreferrer noopener">weight loss and liver fat data</a> announced earlier this year supports the potential for our GLP-1 implant to provide comparable efficacy to semaglutide, the active ingredient in blockbuster products Ozempic and Wegovy, but with the significant benefit of twice-yearly administration," Mendelsohn added.
Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
If available, Vivani intends to utilize research and development incentives and rebates from the Australian government to defray a portion of the costs from the trial.
Since clinical studies conducted in Australia comply with the International Conference on Harmonization guidelines and data generated in Australia are generally acceptable to the FDA and other regulatory authorities, Vivani anticipates using relevant clinical data generated in Australia to support regulatory submissions in other geographies, including the U.S.
Price Action: VANI stock closed at $1.18 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41033979/fda-casts-doubt-on-use-of-merck-bristol-myers-pd-1-cancer-drugs-for-certain-type-of-gastric-cance" target="_blank" rel="noreferrer noopener">FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients</a>.</li>
</ul>

Exclusives

VANI

EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia

Some experts believe Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) products not only help people lose weight and control diabetes, they can help treat the <a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear">country&#8217;s addiction crisis.</a> 
The Novo Nordisk chart illustrates two common technical analysis dynamics that <a href="https://www.benzinga.com/quote/NVO">successful traders can use to profit.</a>
As you can see, the $123 level was support for the stock in April. Then it was support again in early August. And after a recent move higher and a reversal, the stock found support around the same level again.
Support can stay intact for an extended time because of investor and trader psychology. It is because there are traders who sold while the stock was at support. But right after they were done selling, the shares rallied.
When this happened, many of these sellers came to regret their decision to get rid of their shares. Some of them decided to buy their shares back. But, they will only do so if they can buy the shares for the same price they were sold.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="979" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26.png" alt="" class="wp-image-566523" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26.png 979w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26-768x473.png 768w" sizes="(max-width: 979px) 100vw, 979px" /></figure>
Read Also:<a href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic"> Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users</a>
So, when the stock reversed and eventually returned to the support level, these remorseful sellers placed buy orders. And there were so many of these buy orders that it created support at the level which had been support before.
Seller's remorse&nbsp;can make support levels stay intact for an extended period of time.
When a stock drops to a support level, there is a tendency for them to reverse and rally. This is also because of psychology. It happens because some of the buyers experience anxiety.
These buyers are worried they will miss the trade. They know that the sellers will go to whoever is willing to pay the highest price.
As a result, they increase the prices they are willing to pay. Other anxious buyers see this and do the same thing.
This results in a bidding war that pushes the price higher.
If understood and interpreted correctly, technical analysis is the study of investor and trader psychology. Seller's remorse can cause support levels to stay intact for an extended period of time. Buyer's anxiety can make stocks rally after the drop to support levels.
Read Next: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028913/bristol-myers-2seventy-bio-halt-phase-3-trial-for-abecma-in-newly-diagnosed-myeloma">Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability</a>
Photo: Shuttersotck

Technicals

Lose Weight With Novo Nordisk Drugs, Gain Money With Stock

A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid type 2 diabetes (T2D) and opioid use disorder (OUD).
Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is available as Wegovy and Ozempic for weight loss and diabetes, respectively, and liraglutide is sold as Saxenda and Victoza.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41025381/exclusive-novo-nordisk-faces-political-heat-over-weight-loss-drug-prices-ahead-of-e" rel="noreferrer noopener">EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet &#8216;The Real Issue Is With The Middlemen&#8217;</a>.
Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) dulaglutide is available as Trulicity.
Drug overdose <a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824054?guestAccessKey=67ec89b0-a682-4fbf-97d9-1c0054b62d04&amp;utm_source=for_the_media&amp;utm_medium=referral&amp;utm_campaign=ftm_links&amp;utm_content=tfl&amp;utm_term=092524" rel="noreferrer noopener">deaths</a> in the U.S. remain alarmingly high, with an estimated 107,543 fatalities in 2023, primarily due to opioids.
Despite the proven effectiveness of medications for opioid use disorder (OUD) in reducing overdose risk, only about 25% of individuals with OUD receive treatment, and nearly half discontinue it within six months. This highlights the urgent need for alternative OUD therapies.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used to treat type 2 diabetes and obesity, have been shown to modulate dopamine reward pathways and reduce drug rewards, including heroin, in animal studies.
Additionally, anecdotal reports and studies have suggested that semaglutide may reduce drug cravings and offer therapeutic benefits in alcohol and nicotine use disorders.
These findings prompted an investigation into whether semaglutide could potentially help prevent overdoses in OUD patients.
Semaglutide was associated with a significantly lower risk of opioid overdose during a 1-year follow-up compared with other antidiabetic medications, including other GLP-1RAs, with HRs ranging from 0.32 to 0.58. 
The negative control outcome showed no difference between groups. The update signals a potential new use for the blockbuster diabetes medications.
The researchers noted that results need validation from other data resources and study populations. Further research is warranted to investigate the underlying mechanisms, and randomized clinical trials are necessary to corroborate the clinical effects on OUD.
The study utilized six years of data (between December 2017 and June 2023) from over 33,006 patients.
Earlier this year, a comprehensive U.S. study revealed that the use of&nbsp;Ozempic and Wegovy is not associated with an increased&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36509636/novo-nordisks-ozempic-and-wegovy-helps-lose-weight-not-ones-mind-us-study-find-no-increased-suici" rel="noreferrer noopener">risk of suicidal thoughts</a>.
Price Action: NVO stock is up 1.16% at $126.90, and LLY stock is down 0.05% at $924.01 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41031132/amgens-rocatinlimab-has-commercial-potential-despite-competitive-landscape-says-gol" target="_blank" rel="noreferrer noopener">Amgen&#8217;s Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs</a>.</li>
</ul>
Image via Shutterstock

Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users

A new study has found that people with a history of opioid abuse who took Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a href="https://www.benzinga.com/topic/ozempic">Ozempic</a> weight loss drug were significantly less likely to overdose, adding to growing evidence suggesting that the drug, primarily used for diabetes and weight loss, could help manage <a href="https://www.benzinga.com/topic/addiction">drug addiction</a>.
According to the <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.35247?guestAccessKey=67ec89b0-a682-4fbf-97d9-1c0054b62d04&amp;utm_source=for_the_media&amp;utm_medium=referral&amp;utm_campaign=ftm_links&amp;utm_content=tfl&amp;utm_term=092524" target="_blank" rel="noreferrer noopener">study</a>&nbsp;published Wednesday in JAMA Network Open, patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug <a href="https://www.benzinga.com/topic/wegovy">Wegovy</a>, were less than half as likely to overdose compared to those on insulin. People taking semaglutide were 63% less likely to overdose than individuals on DPP-4 inhibitors, another common class of diabetes medication.
Rong Xu, professor of biomedical informatics at Cleveland's Case Western Reserve University, led the research, which had previously linked semaglutide to reductions in alcohol use disorder and smoking. This is the first large-scale study to evaluate opioid overdoses. 
The reduced risk associated with semaglutide persisted across most diabetes treatments, except for Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Trulicity, according to the study, which was first <a href="https://www.bloomberg.com/news/articles/2024-09-25/novo-s-ozempic-reduced-opioid-overdose-risk-research-shows?srnd=phx-latest&amp;sref=TBDibEcD&amp;leadSource=uverify%20wall">reported</a> by Bloomberg.
Read Also<a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on">: Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>
Why It Matters: Drug overdose deaths are at historically high levels in the U.S. 
Over 108,000 people died from an overdose in 2022, <a href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" target="_blank" rel="noreferrer noopener">according to provisional data</a> released by the Centers for Disease Control and Prevention (CDC). In the one-year period ending in January 2024, there were over 76,922 fatal drug overdoses.
These overdose deaths are only part of the severity of the problem. 
&#8220;That overdose number is only looking at overdoses. It&#8217;s not looking at the person who dies of bacterial endocarditis related to their drug and alcohol use,&#8221; <a href="https://www.axios.com/2024/05/31/us-addiction-crisis-drug-use-disorder-mental-illness">said</a> Cara Poland, an addiction medicine doctor at the Michigan State University College of Human Medicine, per Axios.
As powerful new drugs like Ozempic grow in popularity for weight loss, interest is increasing in their potential to curb cravings for substances beyond food. Novo Nordisk is also exploring the drug&#8217;s effects on alcohol consumption in an ongoing clinical trial.
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41025381/exclusive-novo-nordisk-faces-political-heat-over-weight-loss-drug-prices-ahead-of-e">EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet &#8216;The Real Issue Is With The Middlemen&#8217;</a>

Cannabis

Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes

2seventy bio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>)&nbsp;and its partner Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma&nbsp;(idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41020153/2seventy-bio-provides-update-on-karmma-9-study-and-previews-anticipated-strong-third-quarter-reven" rel="noreferrer noopener">stem cell transplant</a>.
"Consistent with our focus on capital allocation and creating value for all stakeholders, we anticipate this decision will conserve over $80 million in near-term expenditures and accelerate our path to breakeven in 2025," said Chip Baird, CEO of 2seventy bio.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38114915/fda-approves-bristol-myers2seventy-bios-abecma-for-earlier-use-in-pretreated-blood-cancer-patient" rel="noreferrer noopener">FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer</a>.
2seventy also reported continued positive momentum in&nbsp;Abecma's expected return to growth in the earlier line setting following the FDA's approval in April 2024.
The company expects third-quarter&nbsp;Abecma&nbsp;U.S. revenue growth of approximately 30%&nbsp;from second-quarter revenue of $54 million. Demand, as measured by new patients undergoing apheresis in the third quarter, is also expected to reflect double-digit growth compared to the second quarter of 2024.
William Blair says while expectations for Abecma are generally low for investors at this point, the ability to maximize the opportunity in the current label would offset concerns about the fixed costs of the cell therapy franchise.
2seventy bio and BMS share equally in all profits and losses related to the development, manufacturing, and commercialization of&nbsp;Abecma&nbsp;in the U.S.
Overall, the announcement suggests moving CAR-T therapies into the earliest lines of treatment may have headwinds given the strong current standard of care. Therefore, we think thoughtful trial designs that reflect the changing standard of care will have the greatest potential of maximizing the CAR-T total addressable market."
Recently, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39532373/novo-nordisk-buys-2seventys-hemophilia-a-program-divestiture-supports-exclusive-focus-on-abecma" rel="noreferrer noopener">cells for autoimmune disease</a>.
2seventy bio will focus exclusively on the commercialization and continued development of&nbsp;Abecma.
Price Action: TSVT stock is down 7.65% at $4.41, and BMY stock is down 2.90% at $49.47 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41028246/flutter-bets-big-on-us-and-global-expansion-21b-revenue-goal-and-5b-buyback-in-sight" target="_blank" rel="noreferrer noopener">Flutter Bets Big On US And Global Expansion: $21B Revenue Goal And $5B Buyback In Sight</a>.</li>
</ul>

Analyst Color

TSVT

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is under mounting political pressure over the high U.S. prices of its blockbuster weight-loss drugs, Ozempic and Wegovy, as the race for the White House heats up. The pricing disparity between the U.S. and other international markets has drawn sharp criticism from lawmakers, putting the company <a href="https://www.benzinga.com/general/biotech/24/09/41010577/novo-nordisk-to-consider-ways-for-patients-to-affordably-access-weight-loss-drugs-ozempic-wegovy-">in the political spotlight.</a>
Ozempic, for example, costs around $969 per month in the U.S., while the same drug is available for as low as $71 in France. Wegovy, another Novo Nordisk drug, is priced at $1,349 in the U.S., versus only $92 in the U.K.
<h3 class="wp-block-heading">CEO Testifies Before Congress: A Focus On PBMs</h3>
On Tuesday, Novo Nordisk&#8217;s CEO, Lars Fruergaard Jorgensen, testified before U.S. lawmakers, addressing the significant price gap between the U.S. and international markets. 
Jorgensen attributed much of the pricing issue to pharmacy benefit managers (PBMs)—the middlemen between pharmaceutical companies and insurers. 
In an exclusive interview with Benzinga on Tuesday, Mauritz Pot, founder and CEO of Tema ETFs, which actively manages the Tema GLP-1, Obesity &amp; Cardiometabolic ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTS#NYSE">HRTS</a>), offered his perspective on what this political showdown means for Novo Nordisk shareholders and the broader healthcare landscape.
According to Pot, Novo Nordisk's primary defense is that even if they reduce list prices, there's no guarantee that these savings will be passed on to the end consumer.
"The U.S. payment system is structured in such a way that even if manufacturers like Novo Nordisk cut their list prices, it won't necessarily result in lower costs for patients. The real issue is with the middlemen and with how much margin they are extracting," Pot said.
<h3 class="wp-block-heading">PBMs: The Real Bottleneck For Consumers</h3>
PBMs have a significant influence over the U.S. pharmaceutical pricing structure, as Pot explained. 
While lowering list prices could help, PBMs may reduce insurance coverage in response, allowing them to maintain their own profit margins. This means patients could still be left with high out-of-pocket costs, even if manufacturers like Novo Nordisk cut prices.
<h3 class="wp-block-heading">Limited Impact on Novo Nordisk&#8217;s Bottom Line</h3>
From an investor&#8217;s perspective, Pot believes that pricing cuts alone are unlikely to significantly hurt Novo Nordisk's revenue or profitability from the U.S. market.
He highlighted that while list prices are high, the actual price paid by insurers and patients is often much lower, meaning Novo's U.S. revenues may remain relatively stable, even if political pressure to reduce prices continues.
The demand for Novo Nordisk's weight-loss drugs remains incredibly strong. Pot explained that even with potential price cuts, the demand for GLP-1 drugs like Ozempic and Wegovy far outpaces supply. This is unlikely to change in the short term, creating a robust growth opportunity for Novo Nordisk.
"Even if the price halves, there&#8217;s still going to be a massive opportunity here," Pot said.
<h3 class="wp-block-heading">Bipartisan Push for Lower Drug Prices</h3>
With the 2024 U.S. presidential election looming, drug pricing has become a hot-button political issue. Both major parties—Republicans and Democrats—agree on the need to reduce prescription drug prices, although they differ on the best mechanisms to achieve this. Regardless of the approach, the push for more affordable drugs is bipartisan.
"Price is being politicized in an election year very clearly," Pot said.
<h3 class="wp-block-heading">Post-Election M&amp;A Activity on the Horizon</h3>
Looking ahead, Pot anticipates a significant increase in M&amp;A activity in the pharmaceutical sector, particularly among companies in the weight-loss and obesity treatment space. 
Smaller biotech firms developing innovative treatments could become attractive acquisition targets, especially after the election.
&#8220;We're likely to see a ramp-up in M&amp;A activity in the sector post-election, regardless of who wins,&#8221; Pot stated.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/09/41008403/consumer-confidence-tumbles-as-concerns-over-labor-market-grow-odds-rise-for-50-b">Consumer Confidence Tumbles As Concerns Over Labor Market Grow, Odds Rise For 50-Basis-Point Interest Rate Cut In November</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Interview

ETFs

HRTS

EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'

Shares of Ventyx Biosciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi. Per the terms of the deal, Sanofi will buy 70,601 of Ventyx&#39;s Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock.&nbsp;
The proceeds from this investment are anticipated to enhance Ventyx&#39;s cash reserves. With the addition of these funds, the combined total of current cash, cash equivalents and marketable securities is expected to support the company&#39;s planned operations until at least the second half of 2026.
<h2>VTYX Grants SNY Exclusive Rights to Investigational Drug</h2>
In return for the $27 million equity investment, Ventyx has granted Sanofi the exclusive opportunity to first negotiate certain rights related to the clinical programs of VTYX&#39;s investigational candidate, VTX3232. Notably, VTX3232 is an oral, selective, central nervous system-penetrant NLRP3 inhibitor, which is being developed for various neuroinflammatory and neurodegenerative indications, including Parkinson&#39;s disease, cardiometabolic disease, Alzheimer&#39;s disease and multiple sclerosis.
Ventyx believes that this strategic deal with Sanofi underscores the potential of VTX3232 to offer a disease-modifying treatment for CNS indications with significant unmet medical needs. The company will also be able to utilize Sanofi&#39;s large resources and prowess in developing treatments for immunological and inflammatory diseases.
Year to date, shares of Ventyx have lost 0.4% compared with the industry&lsquo;s 1.5% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/36/78953.jpg?v=1922698421" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>VTYX&#39;s Development Programs for VTX3232</h2>
Currently, Ventyx is developing VTX3232 for the treatment of Parkinson&#39;s disease and obesity. In early September, the company initiated a phase IIa study to evaluate VTX3232 in patients with early Parkinson&#39;s disease. Top-line results are expected in 2025.
Ventyx is also currently gearing up to initiate a separate 12-week phase II study of VTX3232 by the end of 2024 in patients with obesity and additional cardiovascular and cardiometabolic risk factors. The planned study will assess the impact of VTX3232 on key inflammatory biomarkers and weight change, both as a monotherapy and in combination with a GLP-1 receptor agonist. Top-line data from this obesity study of VTX3232 is also expected in 2025.
<div class="chart_embed">
<h2>Ventyx Biosciences, Inc. Price and Consensus</h2>
<img alt="Ventyx Biosciences, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/9b/1727179627.png" style="height:310px; width:600px" title="" />
Ventyx Biosciences, Inc. price-consensus-chart | Ventyx Biosciences, Inc. Quote
The obesity sector has garnered much interest in 2024 due to its huge untapped market potential. Several biotech firms are competing fiercely to enter this market and are evaluating candidates for the obesity indication.
</div>
The obesity market is currently dominated by two large drugmakers, Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) and Novo Nordisk (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>),&nbsp;with their respective obesity drugs Zepbound (tirzepatide) and Wegovy (semaglutide). Despite having approved drugs in this space, LLY and NVO have been unable to cope with existing demand. Both companies have been investing heavily to ramp up production to meet increasing demand.
However, both NVO&#39;s Wegovy and LLY&#39;s Zepbound are administered as weekly injections. Novo Nordisk, Lilly and some other drugmakers are making oral medicines with different mechanisms of action for obesity, which can improve patient convenience.
<h2>Other Programs in VTYX&#39;s Clinical-Stage Pipeline</h2>
Apart from VTX3232, there are three early to mid-stage candidates in Ventyx&#39;s pipeline, VTX2735 (peripheral NLRP3 inhibitor), VTX002 (S1P1R modulator) and VTX958 (TYK2 inhibitor). While VTX2735 is being evaluated to treat cardiovascular and other systemic inflammatory diseases, VTX002 and VTX958 are under development for ulcerative colitis and Crohn&#39;s disease, respectively.
<h2>VTYX&#39;s Zacks Rank</h2>
Ventyx currently carries a Zacks Rank #3 (Hold).
<a href="https://www.zacks.com/stock/news/2340664/vtyx-stock-rises-on-strategic-equity-investment-deal-with-sny?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2340664">To read this article on Zacks.com click here.</a>

Penny Stocks

Small Cap

Events

Analyst Ratings

VTYX

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) will consider ways to help patients <a href="https://www.benzinga.com/general/biotech/24/09/40997408/miracle-weight-loss-drug-ozempic-to-enter-us-price-negotiations-within-a-year-novo-nordisk-ceo-sa">get affordable prescriptions</a> for weight loss drugs, CEO Lars Fruergaard Jorgensen told members of the U.S. Congress on Wednesday when asked if his company would lower U.S. prices for Ozempic and Wegovy.
Jorgensen sat before the Health, Education, Labor and Pensions Committee, led by Sen. Bernie Sanders (I-Vt.), to answer questions on why Ozempic costs $969 per month in the U.S. versus only $155 per month in Canada, $122 in Denmark, $59 in Germany and $71 in France.
A month&#8217;s prescription for Wegovy in the U.S. costs $1,349, compared to $186 in Denmark, $140 in Germany and $92 in the U.K.
&#8220;You&#8217;re making huge amounts of money in this country and you&#8217;re charging us far more and you haven&#8217;t given me an answer as to why,&#8221; Sanders said to Jorgensen during the hearing.
Sanders then told Jorgensen that pharmacy benefit managers (PBM) would keep both Ozempic and Wegovy on their insurance coverage lists if his company substantially lowered the prices of these drugs in the U.S.
&#8220;I have received commitments in writing from the major PBMs that if Novo Nordisk lowered its list price, they would not limit access to Ozempic and Wegovy and would not take these drugs off of their formularies,&#8221; Sanders said.
Read Also: <a href="https://www.benzinga.com/general/biotech/23/08/34041655/wegovys-massive-demand-novo-nordisk-ceo-expresses-full-confidence-in-catalent-amid-manufacturing-">Wegovy&#8217;s Massive Demand: Novo Nordisk CEO Expresses Full Confidence In Catalent Amid Manufacturing Hurdles</a>
&#8220;Given this fact, will you commit today that Novo Nordisk will substantially reduce the list price of these drugs in the United States so that the American people are not paying higher prices, far higher prices for these drugs than the people in Europe and Canada?&#8221;
Jorgensen said his company will examine ways to give U.S. patients &#8220;access to affordable medicine&#8221; after hearing of this commitment for the first time.
&#8220;Thank you, senator, for for that information. That&#8217;s new information for me,&#8221; he said.
&#8220;Anything that will help patients get access to affordable medicine, we&#8217;ll be happy to look into.&#8221;
But he said he was a bit concerned by the commitment because an insulin medicine made by Novo Nordisk was dropped from PBM&#8217;s formularies after the company dropped internet pricing for the drug last year.
&#8220;I have a bit of concern how this could play out but anything that can help patients get access to the medicines they need at affordable price point will be happy to collaborate around that,&#8221; Jorgensen said. 
Sanders asked Jorgensen if he would be willing to sit down with governors to work on an agreement to lower the prices for Ozempic and Wegovy, based on the commitment from PBMs.
&#8220;I&#8217;d be happy to, as I said to anything that helps patients,&#8221; he said. &#8220;I don&#8217;t know under which conditions such a promise comes. I haven&#8217;t seen any of that.&#8221;
NVO Price Action: Novo Nordisk rose 2.25% to $126.48 into Tuesday&#8217;s mid-day trading.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/23/10/35449786/weight-loss-drugs-wegovy-ozempic-gain-traction-with-millennials-high-earners-new-survey-results">Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results</a></li>
</ul>
Photo: Natalia Varlei On Shutterstock

Government

Insurance

Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO

WIIM

Novo Nordisk shares are trading higher as CEO Lars Jorgensen's testifies before the Senate on pricing.

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $106,450 and 8, calls, for a total amount of $407,096.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $150.0 for Novo Nordisk during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Novo Nordisk stands at 634.4, with a total volume reaching 361.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $90.0 to $150.0, throughout the last 30 days.
<h3>Novo Nordisk 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727191852_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$17.75</td>
<td>$17.4</td>
<td>$17.56</td>
<td>$120.00</td>
<td>$105.3K</td>
<td>22</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$7.1</td>
<td>$6.95</td>
<td>$7.03</td>
<td>$130.00</td>
<td>$67.2K</td>
<td>1.9K</td>
<td style="text-align: right;">109</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$25.65</td>
<td>$25.25</td>
<td>$25.25</td>
<td>$150.00</td>
<td>$50.5K</td>
<td>82</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.8</td>
<td>$9.75</td>
<td>$9.8</td>
<td>$125.00</td>
<td>$49.0K</td>
<td>404</td>
<td style="text-align: right;">65</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.6</td>
<td>$10.4</td>
<td>$10.5</td>
<td>$125.00</td>
<td>$47.2K</td>
<td>1.2K</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Novo Nordisk</h3>
<ul>
<li>Trading volume stands at 1,723,363, with NVO's price up by 1.47%, positioned at $125.52.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 43 days.</li>
</ul>
<h3>What The Experts Say On Novo Nordisk</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Novo Nordisk's Options: A Look at What the Big Money is Thinking

<a href="https://www.youtube.com/live/bAhpNRRkOFg?si=wFdRoZnospIp2NB2" title="https://www.youtube.com/live/bAhpNRRkOFg?si=wFdRoZnospIp2NB2">https://www.youtube.com/live/bAhpNRRkOFg?si=wFdRoZnospIp2NB2</a>

US Senator Bernie Sanders Says Pharmacy Benefit Managers Have Committed To Expand Coverage For Novo Nordisk's Weight-loss Drugs If Company Reduces List Price

'LIVE: Novo Nordisk CEO Lars Jorgensen testifies before Senate on weight loss drugs pricing — 9/24/24' - CNBC

Macro Economic Events

Market Summary

SMAR

Benzinga Market Summary: China Announces Stimulus, Novo Nordisk CEO To Testify To Senate, Smartsheet To Be Acquired By Blackstone And Vista

Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a &#8220;miracle&#8221; weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.
What Happened: Jorgensen is scheduled to testify before a <a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on">Senate committee on Tuesday</a> to discuss U.S. pricing for Ozempic and the weight loss drug Wegovy. The comments align with Wall Street analysts&#8217; expectations that Ozempic will be on the 2027 price negotiation list, which will be announced in February 2025, Reuters reported.
Last week, another Novo executive indicated that Ozempic would &#8220;very likely&#8221; be included in the 2027 list. A month&#8217;s supply of Ozempic currently lists at $935.77 in the U.S., while Wegovy lists for $1,349.02 per month, although insurance often reduces these costs.
The Inflation Reduction Act of 2022 permits Medicare to negotiate prices for costly prescription drugs, impacting millions of Americans. Both Ozempic and Wegovy have faced scrutiny from lawmakers over their high prices in the U.S.
Jorgensen noted that the net price of Ozempic has decreased by about 40% since its U.S. introduction, and Wegovy&#8217;s net price has similarly declined since its launch. He expects net prices for both drugs to continue to fall under current market conditions.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40989263/long-term-medical-cannabis-use-has-no-significant-harmful-effects-on-memory-or-impulse-control-n?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Long-Term Medical Cannabis Use Has No Significant Harmful Effects On Memory Or Impulse Control, New Study</a>
Why It Matters: The upcoming Senate hearing, scheduled for Tuesday, will see Lars Fruergaard Jorgensen face rigorous questioning from U.S. lawmakers regarding the high prices of Ozempic and Wegovy. Senator Bernie Sanders, chair of the Senate Committee on Health, Education, Labor, and Pensions, has been vocal about the exorbitant costs of these medications.
In a previous interview, Jorgensen <a href="https://www.benzinga.com/general/biotech/24/08/40550961/novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-">defended the high U.S. prices</a>, arguing that these drugs help reduce the economic burden of obesity-related health issues, which costs the U.S. over $400 billion annually. He dismissed accusations that Novo Nordisk operates as a drug cartel as &#8220;unfounded.&#8221; 
Additionally, the issue of counterfeit Ozempic has emerged as a significant concern. Criminals have been <a href="https://www.benzinga.com/general/biotech/24/09/40737027/fake-ozempic-targets-weight-loss-market-forged-batches-an-international-concern">distributing fake versions</a> of the drug by forging batch numbers, which has become an international issue. The World Health Organization and Interpol have both issued warnings about these counterfeit products. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Novo Nordisk And Corbus Pharmaceutical Stocks Plummet</a></li>
</ul>
Photo via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing

BioAge, obesity drug developer, upsizes proposed IPO

Next frontier in anti-obesity landscape: oral GLP-1s with potential OTC switch

Viking Therapeutics Is A Buy For Some Investors, But Beware The Sizeable Risks

Evotec, Novo Nordisk forms technology development partnership for stem cell-based therapies

Evotec, Novo Nordisk form technology development partnership for stem cell-based therapies

BioAge stock rallies 29% following upsized $198M IPO

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target o...

Novo Nordisk (0QIU) Receives a Buy from J.P. Morgan

Here are the Medicare Part D drugs expected to face 2025 price negotiations

Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales

Novo Nordisk (NVO) has released an update. Novo Nordisk A/S has announced a significant share repurchase program, with up to DKK 20 billion allocat...

Novo Nordisk Launches Major Share Buyback

ABBV

ALPMF

ALPMY

AMGN

BIOA

BNTX

GILD

NONOF

REGN

RHHBF

RHHBY

TEVA

VKTX

Screenshot 2024-09-10 at 4.29.40 PM

BRTX

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation

NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results

Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®

Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors

Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Management

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

ALGS

ANVS

CRDL

DRNA

MAIA

NNVC

NOVO

PLRX

SILO

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Novo Nordisk

Noticias

Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL